Lanxess-backed converter of feedstocks into chemicals revises IPO terms.
BioAmber, a Canada-based maker of bio-based succinic acid, has revised its IPO terms to 8 million shares being offered at between $10 and $12 per share plus an attached warrant to purchase 0.5 shares of common stock at an exercise price of $11.
The company previously planned to sell 8 million shares at between $15 and $17.
Montreal-based BioAmber expects to trade on the NYSE under ticker symbol BIOA, with Credit Suisse serving as lead underwriter.
Chemicals group Lanxess invested…
